Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up

Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up

Hypophysitis, secondary to programmed cell death 1 protein (PD1) and programmed cell death 1 ligand 1 (PDL1) inhibitors, were thought to be rare, with only a few studies describing more than one case with long-term follow-up. The aim of the present study was to describe the clinical, laboratory, and...

Full description

Bibliographic Details
Main Authors:	Manon Levy, Juliette Abeillon, Stéphane Dalle, Souad Assaad, Françoise Borson-Chazot, Emmanuel Disse, Gérald Raverot, Christine Cugnet-Anceau
Format:	Article
Language:	English
Published:	MDPI AG 2020-10-01
Series:	Journal of Clinical Medicine
Subjects:	hypophysitis adrenal insufficiency immunotherapy nivolumab pembrolizumab programmed cell death 1 protein
Online Access:	https://www.mdpi.com/2077-0383/9/10/3280

Similar Items

Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report
by: Sofia Antoniou, et al.
Published: (2021-09-01)

Hypophysitis induced by ipilimumab and nivolumab combination therapy for advanced renal cell carcinoma: A case report
by: Aoi Motonaga, et al.
Published: (2021-09-01)

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients
by: Bal, W., et al.
Published: (2022)

Combined granulomatous and lymphocytic hypophysitis presenting as pituitary incidentaloma in a middle-aged woman
by: Abhay Gundgurthi, et al.
Published: (2012-01-01)

Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report
by: Fumi Kikuchi, et al.
Published: (2021-04-01)

A rare cause of hypophysitis: tuberculosis
by: Ates Ihsan, et al.
Published: (2017-10-01)

Metástasis hipofisaria Hypophyseal metastasis
by: Miguel Ángel Yanes Quesada, et al.
Published: (2009-04-01)

Graves’ Disease During Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
by: Mathilde Peiffert, et al.
Published: (2021-04-01)

Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis
by: Sahityasri Thapi, et al.
Published: (2019-09-01)

Clinical and hormonal characteristics of patients with different types of hypophysitis: a single-center experience
by: Narin Nasiroglu Imga, et al.

Granulomatous hypophysitis in a postpartum patient: A case report
by: Alexey Youssef, et al.
Published: (2018-01-01)

Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives
by: Yating Zhao, et al.
Published: (2021-07-01)

Lymphocytic hypophysitis masquerading as pituitary adenoma
by: Rajneesh Mittal, et al.
Published: (2012-01-01)

Idiopathic granulomatous hypophysitis: A report of an uncommon disorder
by: Shubhangi Vinayak Agale, et al.
Published: (2018-01-01)

Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?—Lessons From Value Assessment With ASCO-VF and ESMO-MCBS
by: Qian Jiang, et al.
Published: (2020-12-01)

Xanthomatous hypophysitis: A rare case report with review of literature
by: Hema Kini, et al.
Published: (2019-01-01)

Ipilimumab (Immune Checkpoint Inhibitors) Hypophysitis
by: Margot Stagnetto, et al.
Published: (2020-11-01)

Xanthomatous Hypophysitis Presenting in an Adolescent Girl: A Long-Term Follow-Up of a Rare Case and Review of the Literature
by: Jeanne Sze Lyn Wong, MBBS, MRCPH, et al.
Published: (2021-05-01)

Hypophysitis following Treatment with Ustekinumab: Radiological and Pathological Findings
by: Ana M. Ramos-Leví, et al.
Published: (2018-03-01)

A Rare Case of Autoimmune Hypophysitis Presenting as Temperature Dysregulation
by: Ankur Jain, et al.
Published: (2015-02-01)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
by: Muhammad Zubair Afzal, et al.
Published: (2018-07-01)

Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody
by: Hiroshi Matsuoka, et al.
Published: (2020-07-01)

Idiopathic granulomatous hypophysitis presenting with galactorrhea, headache, and nausea in a woman: a case report and review of the literature
by: Guive Sharifi, et al.
Published: (2019-11-01)

Cancer immunotherapy experience in the Integral Oncology Centre “Diana Laura Riojas de Colosio”, Médica Sur Hospital
by: Ricardo Fernández-Ferreira, et al.
Published: (2019-12-01)

A rare case report of hypophysitis in pituitary macroadenoma mimicking pituitary apoplexy
by: Akkayasamy Kowsalya, et al.
Published: (2021-01-01)

Steroid Responsive Xanthomatous Hypophysitis Associated with Autoimmune Thyroiditis: A Case Report
by: Ji Young Joung, et al.
Published: (2013-03-01)

Clinical Characteristics, Management, and Outcome of 22 Cases of Primary Hypophysitis
by: Sun Mi Park, et al.
Published: (2014-12-01)

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
by: Jeffrey M. Conroy, et al.
Published: (2019-01-01)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
by: Carl Morrison, et al.
Published: (2018-05-01)

Targeting the PD-1/PD-L1 axis in the treatment of lung cancer
by: Matikas Alexios, et al.
Published: (2016-03-01)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
by: Justin C. Moser, et al.
Published: (2019-12-01)

Clinical efficacy and safety of anti PD-1/PD-L1 antibodies as monotherapy in patients with non-small-cell lung cancer
by: Marta Zayas-Soriano, et al.
Published: (2021-01-01)

A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study
by: Hamatake, M., et al.
Published: (2022)

Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
by: Wagner LM, et al.
Published: (2017-04-01)

Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
by: Oncale MB, et al.
Published: (2017-02-01)

Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy
by: Pawel Teterycz, et al.
Published: (2020-10-01)

Trial watch: Immune checkpoint blockers for cancer therapy
by: Claire Vanpouille-Box, et al.
Published: (2017-11-01)

Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the ‘panacea’ for all patients?
by: Alessandro Morabito
Published: (2018-02-01)

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
by: Sarabjot Pabla, et al.
Published: (2019-02-01)

Immunotherapy in Small Cell Lung Cancer
by: Giovanna Esposito, et al.
Published: (2020-09-01)

Cannot write session to /tmp/vufind_sessions/sess_h42o91qeka8rlvbtb98ddbpfa6